Selective GLP-1 receptor agonists have been the workhorse of incretin pharmacology for over a decade. What the recent literature on tirzepatide and retatrutide demonstrates is that engaging additional related receptors - GIP and glucagon - produces phenotypes in preclinical and clinical models that single-receptor agonists do not.
From mono to multi
The conceptual shift is from receptor selectivity as a design goal to balanced multi-receptor engagement as a design goal. Tirzepatide engages GIP and GLP-1 receptors; retatrutide additionally engages the glucagon receptor. Each receptor contributes a distinct metabolic signaling arm.
What this means for the bench
For researchers designing in vitro and pre-clinical in vivo studies, the triple-agonist class represents both a set of probe tools and a set of methodological challenges. Receptor contribution analysis becomes harder. The published literature is still developing its standard assay panels for this class.